
Opinion|Videos|February 10, 2025
Shared Decision-Making in Tardive Dyskinesia
Panelists discuss how TD treatment can be optimized through individualized approaches that consider patient-specific factors like symptom severity, comorbidities, concurrent medications, and daily routines, utilizing tools like titration kits to carefully adjust VMAT2 inhibitor dosing while monitoring response and tolerability to achieve the best possible outcomes for each patient.
Advertisement
Episodes in this series

Video series above is prompted by the following:
- How can treatment strategies for TD be individualized (eg, titration kits) based on patient-specific factors?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
2
Denosumab Biosimilars Conexxence and Bomyntra Receive Interchangeability Designation
3
Improving RSV Vaccine Coverage Could Prevent Thousands of Severe Cases in Older Adults
4
PCV20 Demonstrates Real-World Effectiveness Against Pneumonia in Older Adults
5

















































































































































































































